Analytical Data
-
Gene name
FLI1
- Application
-
Alternative Names
Friend leukemia integration 1 transcription factor(Proto-oncogene Fli-1)(Transcription factor ERGB)
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q01543
-
Expression Region
1-452aa
-
Molecular Weight
57.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The FLI1 protein, part of the E26 transformation-specific (ETS) transcription factor family, plays a crucial role in various biological processes, including hematopoiesis, endothelial differentiation, and vascular development. Its importance is highlighted by its involvement in some cancers, particularly Ewing's sarcoma, where FLI1 is often found in fusion with the EWSR1 gene, resulting in a potent oncogenic factor. Research into FLI1 recombinant proteins aims to elucidate its functional mechanisms and regulatory pathways, providing insights into its role in normal physiology and disease states. The expression and purification of FLI1 as a recombinant protein allow for detailed biochemical studies, structure-function analyses, and potential therapeutic applications. By characterizing the interactions between FLI1 and its target genes or proteins, scientists can better understand its contribution to cell signaling pathways and the development of specific malignancies. Furthermore, the use of FLI1 recombinant proteins in drug discovery and development could lead to innovative treatment strategies for cancers associated with FLI1 dysregulation. Through these investigations, researchers seek to unravel the complexities of FLI1’s role in cellular processes and its potential as a target for therapeutic intervention, paving the way for advancements in oncology and regenerative medicine.
